molecules of the month


oral BET inhibitor

4.5 mg QD, phase I/II for cancer

from bromodomain-focused HTS, SBDD

Journal of Medicinal Chemistry

Bristol Myers Squibb

1 min read

The BMS BET inhibitor, BMS-986158, is in a Ph. I/IIa trial in advanced cancers. During the optimization of the molecule from a carbazole hit, the authors employed a bold scaffold-hopping strategy involving changing the direction of the carbazole core in order to better access a hydrophobic region of the target. The proposed new binding mode was confirmed by X-ray co-crystallography. The molecule’s triazole ring also interestingly binds in a manner in which both unsubstituted N atoms appear to be engaged as hydrogen bond acceptors to different hydrogen bond donors in the protein (Asn140 for one, a water-mediated H-bond to Tyr97 for the other).

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: